Greenwich LifeSciences Updates on Screening Progress
STAFFORD, Texas — Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, has recently announced significant advancements in its Phase III clinical trial, FLAMINGO-01. This trial aims to evaluate GLSI-100, an innovative immunotherapy designed to prevent recurrences of breast cancer. The Company has reached an impressive milestone by screening over 1,000 patients, which underlines the strong interest shown by both physicians and patients alike.
FLAMINGO-01 Milestone Achieved
The screening progress reflects the Company’s sustained effort, maintaining a rate of about 150 patients screened each quarter, translating to approximately 600 patients annually across 140 active sites, including 40 sites in the US and 100 sites in Europe. Greenwich LifeSciences is currently evaluating strategies to proceed with participant enrollment in both the HLA-A*02 and non-HLA-A*02 study arms. These plans will continue until an interim analysis can inform the optimal size and strategy for each arm of the trial.
CEO Insights on the Progress
CEO Snehal Patel expressed enthusiasm about the screening milestone, commenting, "The confirmation of 1,000 screened patients validates the high level of interest from doctors and patients, particularly as clinical site set-up in Europe has accelerated the trial's momentum. Additionally, the enthusiasm from other global countries wanting to participate reflects this strong demand. This high screening rate presents the Company with multiple strategic options moving forward, including the flexibility for further enrollment through several interim analyses and the potential to assess efficacy across different HLA types with larger patient groups."
Investigating GLSI-100's Potential
FLAMINGO-01 (NCT05232916) is a carefully designed Phase III trial assessing the safety and effectiveness of GLSI-100, a combination of GP2 and GM-CSF, specifically in patients who exhibit HER2 positive breast cancer characteristics. Participants include those who have residual disease or high-risk pathologic complete response post-surgery after undergoing both neoadjuvant and postoperative trastuzumab treatment. Led by Baylor College of Medicine, the trial currently engages clinical sites in the US and Europe with intentions to expand to a total of 150 global sites. The study aims to randomize approximately 500 patients to receive either GLSI-100 or a placebo, while also planning to treat up to 250 patients with other HLA types in a separate treatment arm.
Evaluating Efficacy and Safety
The trial is strategically set to determine a hazard ratio of 0.3 in terms of invasive breast cancer-free survival, requiring 28 events to conduct an interim analysis aimed at establishing superiority and futility. This robust sample size is expected to yield 80% power, provided that the annual event rate in the placebo group reaches or exceeds 2.4%.
Understanding Breast Cancer and HER2
Breast cancer remains a significant concern, affecting one in eight U.S. women over their lifetimes, with approximately 300,000 new diagnoses and an estimated 4 million survivors each year. The HER2 protein is a crucial factor since it is present in about 75% of breast cancers at varying expression levels. This underscores the importance of targeted therapies like GLSI-100 in addressing this widespread condition.
Company Overview
Greenwich LifeSciences, as a dedicated clinical-stage biopharmaceutical entity, is advancing the development of GP2—an immunotherapy aimed at preventing breast cancer recurrences in patients post-surgery. The Company has embarked on the FLAMINGO-01 Phase III clinical trial to rigorously evaluate this therapeutic approach. To learn more about Greenwich LifeSciences, visit their website.
Frequently Asked Questions
What is the FLAMINGO-01 trial?
FLAMINGO-01 is a Phase III clinical trial that studies GLSI-100's effectiveness in preventing breast cancer recurrences in specific patient populations.
How many patients has Greenwich LifeSciences screened so far?
As of the latest update, more than 1,000 patients have been screened in the FLAMINGO-01 trial.
What does GLSI-100 involve?
GLSI-100 is an immunotherapy composed of a combination of GP2 and GM-CSF, aimed at treating HER2 positive breast cancer patients.
What is the goal of the interim analysis in the trial?
The interim analysis seeks to evaluate efficacy and safety based on the occurrence of specified events during the trial.
How can I get involved with FLAMINGO-01?
Individuals interested in participating or learning more can contact the Company or check the website for more information on the trial.
